Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administration.
We have recently found that matrix metalloproteinases (MMPs) are targets for T-cell and B-cell reactivity in experimental arthritis. In the present article, we investigate whether modulation of MMP-specific T-cell responses could influence the course of adjuvant arthritis (AA). Lewis rats were treated nasally with MMP peptides prior to or after AA induction. Administration of the MMP-10 or the MMP-16 peptide prior to AA induction reduced the arthritic symptoms. In contrast, administration of the MMP-10 peptide after AA induction aggravated the arthritic symptoms. The present study shows the possible usefulness of MMP peptides for immunotherapy. However, a clear understanding of proper timing of peptide administration is crucial for the development of such therapies.
van Bilsen
Jolanda H M
JH
Department of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, Utrecht University, The Netherlands.
Wagenaar-Hilbers
Josée P A
JP
van der Cammen
Maarten J F
MJ
van Dijk
Mariska E A
ME
van Eden
Willem
W
Wauben
Marca H M
MH
D000281:Administration, Intranasal; D000818:Animals; D001169:Arthritis, Experimental / Q000276:immunology* / Q000503:physiopathology / Q000628:therapy*; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D019278:Matrix Metalloproteinase 3 / Q000008:administration & dosage / Q000276:immunology; D020782:Matrix Metalloproteinases / Q000008:administration & dosage / Q000276:immunology*; D010455:Peptides / Q000008:administration & dosage / Q000276:immunology; D051381:Rats; D011917:Rats, Inbred Lew; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
D010455:Peptides; D020782:Matrix Metalloproteinases; D019278:Matrix Metalloproteinase 3